Abstract
Transplant associated thrombotic microangiopathy is a severe complication of Hematopoeitic stem cell transplantation. Although there is agreement in terms of diagnostic criteria, treatment options are not clarified yet. We present a patient aged 2.6 years who developed transplant associated thrombotic microangiopathy after allogeneic bone marrow transplantation and to discuss both risk factors and possible spontaneous remission of transplant associated thrombotic microangiopathy.
This is a preview of subscription content, log in via an institution to check access.
References
Ho VT, Cutler C, Carter S et al (2005) Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoetic stem cell transplantation. Biol Blood Marrow Transpl 11:571–575
Uderzo C, Bonanomi S et al (2006) Risk factors and severe outcome in Thrombotic Microangiopathy after allogeneic hematopoetic stem cell transplantation. Transplantation 82:638
Cutler C, Henry NL, Magee C et al (2005) Sirolimus and thrombotic microangiopathy after allogeneic hematopoetic stem cell transplantation. Biol Blood Marrow Transpl 11:551–557
Stavrou E, Lazarus HM (2010) Thrombotic microangiopathy in hematopoetic cell transplantation: an update. Mediterr J Hemat Infect Dis 2(3):e 2010033. doi:10.4084/MJHID.2010.033
Shimoni et al (2004) Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced intensity conditioning. The incidence is not reduced. Biol Blood Marrow Transpl 10:484
Busca A, Uderzo C (2000) Bone marrow transplant associated thrombotic microangiopathy. Hematology 5:53
Grigg a et al (1995) Disseminated fungal infection and early onset microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transpl 15:795
Uderzo C, Fumagilli M et al (2000) Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing BMT. Bone Marrow Transpl 26:1005
Cho BS, Yahng SA, Lee SE et al (2010) Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoetic stem cell transplantation. Transplantation 90(8):918–926
Moore JC, Arnold DM, Leber BF et al (2007) Intravenous immunoglobulins as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura. Vox Sang 93:173–175
Wolff d, Wilhelm s, Hahn J et al (2006) Replacement of calcineurin inhibitors with daclizumab in patients with transplant associated microangiopathy or renal insufficiency associated with GVHD. Bone Marrow Transpl 38:445–451
Wy Au, Ma ES, Lee TL et al (2007) Successful treatment of thrombotic microangiopathy after hematopoetic stem cell transplantation with rituximab. Br J Hematol 137:475–478
Ho VT, Linden E, Revia c et al (2007) Hepatic veno occlusive disease after hematopoetic stem cell transplantation: review and update on the use of Defibrotide. Semin Thromb Hemost 33:373–388
Bullery SR, Strahm B, Doyle J et al (2007) Defibrotide for the treatment of VOD in children. Pediatr Blood and cancer 48:700–704
Corti p, Uderzo c et al (2002) Defibrotide as promising treatment of thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transpl 29:542
Ulutin ON (1993) Anti thrombotic effect and clinical potential of DFT. Semin Thromb Hemost 19:186
Laski bl, Goebel J, Davis S, Jodele S (2011) Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation- associated thrombotic microangiopathy. Blood 118(6):1452–1462
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marwah, P., Soni, R., Faulkner, L. et al. Remission of Microangiopathy in Transplanted Thalassemic Child. Indian J Hematol Blood Transfus 30 (Suppl 1), 356–358 (2014). https://doi.org/10.1007/s12288-014-0404-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-014-0404-2